| INTRODUC TI ON
Patients with severe haemophilia A experience spontaneous bleeding episodes into joints, muscles and soft tissue 1 ; over time, joint bleeding episodes can lead to haemophilic arthropathy. 1 The standard of care for severe haemophilia A is prophylaxis with a factor VIII (FVIII) product, which can prevent bleeding episodes and joint damage. 1, 2 Prophylaxis, however, is a costly and burdensome treatment, with infusions typically required several times per week. 1 Consequently, in countries such as China, in which access to haemophilia care is limited and patient incomes are low, most patients with haemophilia are treated on-demand, with FVIII administered at the time of a bleeding episode, and some patients may receive no treatment at all. 3, 4 Lack of access to FVIII prophylaxis in some Chinese regions has historically led to this population being undertreated, which subsequently increases the likelihood of joint damage and compromises health-related quality of life in patients with haemophilia A. 6 It is possible that for this reason the joint status and treatment history of the Chinese patients differ from other populations. In 1 study of 213 Chinese patients with haemophilia A or haemophilia B, >90% had haemophilic arthropathy by age 6-9 years. 7 Ideally, patients with haemophilia in China should receive individualized prophylaxis as recommended by the World Federation of Hemophilia (WFH). 1, 8 Low-dose prophylaxis has been explored as a cost-saving approach to treatment of Chinese patients with haemophilia 5, 9 and results have been encouraging. Patients have experienced fewer joint bleeding episodes and some improvement in daily activities compared with on-demand treatment. 10 For these reasons, it should be considered an initial step in haemophilia care in patients where high-dose prophylaxis is not required or not possible due to the economic burden. gram, which enrolled children, adolescents, and adults with severe haemophilia A at sites worldwide. 13, 14 The efficacy of prophylaxis 9, 16 and superiority of prophylaxis over on-demand treatment 17 have been demonstrated in Chinese patients treated with sucrose-formulated recombinant FVIII (rFVIII-FS; Kogenate ® FS; Bayer), which has the same amino acid sequence as BAY 81-8973. 18 To evaluate the efficacy and safety of BAY 81-8973 specifically in Chinese patients with haemophilia A, we examined data from the LEOPOLD II trial, which enrolled 23 patients from China. The subanalysis also explored whether treatment history in Chinese patients affected efficacy and safety.
| ME THODS

| Study design and patients
LEOPOLD II was a multinational, open-label, randomized, crossover phase 2/3 study designed to demonstrate the superiority of BAY 81-8973 prophylaxis over on-demand treatment in patients with severe haemophilia A. 13 The design and results of this study have been previously described. 13 In brief, patients were eligible for LEOPOLD II if they were males aged 12-65 years, had severe haemophilia A, were receiving on-demand treatment at screening and had not received regular prophylaxis for >6 consecutive months in the previous 5 years, had ≥150 exposure days (EDs) to any FVIII product and had no current or history of 
| Efficacy, safety and pharmacokinetic assessments
The primary efficacy endpoint was the annualized bleeding rate were determined using the chromogenic assay and the one-stage assay. Pharmacokinetic (PK) assessments in LEOPOLD II were performed only in a subset of patients recruited at centres in Japan. PK data for Chinese patients, including three paediatric patients (age <18 years), were available from the LEOPOLD I study; methods and results for both of these studies have previously been published.
14,15
| Statistical analysis
A subanalysis was performed to assess the efficacy of prophylaxis versus on-demand treatment in all Chinese patients receiving BAY 81-8973 in the LEOPOLD II study. Evaluated bleed outcomes included ABR for all bleeds, joint bleeds, spontaneous bleeds and trauma-related bleeds for both Chinese and non-Chinese patients and were calculated arithmetically in addition to calculations of mean, standard deviation, median and quartiles. Direct comparisons between Chinese and non-Chinese patients were made for all bleed and joint bleed ABRs. Data were analysed for the 12 months prestudy, the first and last 6 months on-study, and the total 12-month study period. Wilcoxon rank sum tests were used for all comparisons.
| RE SULTS
| Patients
A total of 80 patients were treated with BAY 81-8973 in LEOPOLD II, including 23 patients enrolled at five sites in China and 57 patients enrolled at sites outside China. Median age was similar for the Chinese and non-Chinese patients, but differences were seen between groups in clinical characteristics, including bleeding history and the percentage of patients with target joints (Table 1) .
Specifically, 100% of Chinese patients had target joints at baseline, compared with 86% of non-Chinese patients. Compared with nonChinese patients, Chinese patients also had a higher median age at diagnosis (1.3 vs 2.3 year) and a higher median age at first treatment (1.6 vs 2.9 year). BAY 81-8973 treatment assignments were identical for Chinese and non-Chinese patients, with 74% of patients in each group receiving prophylaxis and 26% treated on-demand (Table 1) .
| Treatment exposure
Patients were only considered eligible for the study if they had ac- 
| Efficacy
BAY 81-8973 prophylaxis significantly decreased ABR in Chinese and non-Chinese patients who had previously been treated on-demand, compared with those who continued on-demand treatment during LEOPOLD II (Table 2 and Figure 1) . In Chinese patients, median ABR for Chinese and non-Chinese patients receiving prophylaxis were significantly lower than those for patients treated on-demand during both the first and last 6 months of the study (Table 2 ). Thus, although
Chinese patients receiving prophylaxis during LEOPOLD II generally had higher prestudy ABRs compared with non-Chinese patients, ABRs during the study were comparable for both groups (Table 2) .
During LEOPOLD II, a total of 499 bleeding episodes occurred in
Chinese patients (432 in the on-demand group; 67 in the combined prophylaxis group). Most bleeding episodes were spontaneous (69.5%
for on-demand; 74.2% for combined prophylaxis) and occurred in joints (72.7% for on-demand; 83.6% for combined prophylaxis). In the on-demand group, 314 bleeding episodes occurred in patients with target joints, of which 262 (83.4%) were into target joints; in the combined prophylaxis group, of 56 bleeding episodes occurring in patients with target joints, 31 (55.4%) were into target joints. Most bleeds 92.5% in the combined prophylaxis group), as rated by the patient.
More than 90% of bleeding episodes in Chinese patients in both the on-demand and combined prophylaxis groups were treated with ≤2 BAY 81-8973 infusions; doses to treat acute bleeds varied between on-demand and prophylaxis groups (Table 3 ). Response to treatment of bleeding episodes with BAY 81-8973 was rated by patients as excellent or good for 54.9% of 432 bleeds in the on-demand group and 62.9% of 62 bleeds in the combined prophylaxis group (treatment response was missing for 5 bleeds in the prophylaxis group).
| Pharmacokinetics and FVIII recovery
Pharmacokinetic data from the LEOPOLD studies were available for 10 Asian patients (6 from China and 4 from Japan) and 32 non-Asian patients. No significant differences were seen in half-life, dose-normalized area under the curve, or dose-normalized maximum concentration between Asian and non-Asian patients (Table 4) .
Median FVIII recovery in Chinese patients measured using the chromogenic assay and based on a nominal dose of 50 IU/kg was 1.7-2.1 kg/ dL at the start of BAY 81-8973 dosing and 1.7-2.0 kg/dL after 6 months.
FVIII recovery measured using the one-stage assay did not differ relevantly from results obtained using the chromogenic assay.
| Safety
Adverse events were reported in 9 of the 23 Chinese patients Pharmacokinetic data were available from 10 Asian patients, including six patients from China who had PK parameters measured in the LEOPOLD I study. In general, PK data for Asian patients were within the range of values seen for non-Asian patients. This finding is as expected because ethnic differences in the PK parameters of BAY 81-8973 are unlikely, given that clearance of endogenous human FVIII is not mediated by drug-metabolizing enzymes having a genetic polymorphism. 19 Caring for patients with haemophilia in some regions of China is challenging owing to insufficient healthcare infrastructure and experience, lack of treatment affordability and accessible insurance, and low disease awareness in the community. As a result, in some areas of China, many patients receive little or no treatment. 4 Even low-dose, short-term prophylaxis treatment provides some clinical benefit for these patients, 9 indicating that standard-dose prophylaxis as recommended by the WFH would have substantial effects on clinical outcomes and quality of life. 1, 8 Indeed, results of the present study indicate that the benefits of standard-dose prophylaxis for Chinese patients would likely be similar to those observed for the rest of the world. Nikki Church https://orcid.org/0000-0001-7618-6137
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